ESMO 2018 | What’s next for next for NETs: novel targeted therapies for neuroendrocrine tumors
In this video, Rocio Garcia-Carbonero, MD, PhD, of the University Hospital of 12 de Octubre, Madrid, Spain, provides a detailed review of novel targeted therapies being developed for neuroendrocrine tumors (NETs). Dr Garcia-Carbonero explores the targets and proven clinical effects of new angiogenesis inhibitors, tyrosine kinase inhibitors, antibody-drug conjugates and bispecific antibodies, while expressing particular excitement about the prospects of lenvatinib from the TALENT trial (NCT02678780). This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up